The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3681-9
Abstract: Background[177Lu]Lu-PSMA-617 is a well-tolerated therapy for the treatment of metastatic prostate cancer. However, because of the mainly renal excretion of the tracer, the kidneys are one of the most limiting organs. The purpose of this… read more here.
Keywords: psma 617; 177lu psma; metastatic prostate; prostate cancer ... See more keywords
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3751-z
Abstract: PurposeRadioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim… read more here.
Keywords: prostate; psma 617; 177lu psma; prostate cancer ... See more keywords
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04317-4
Abstract: PurposeThe aim of this study was to investigate the time- and dose-dependency of DNA double-strand break (DSB) induction and repair in peripheral blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA.MethodsBlood samples from 16… read more here.
Keywords: 177lu psma; time; prostate cancer; blood ... See more keywords
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04612-0
Abstract: Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-targeted radioligand therapy (PRLT) with the alpha-emitter 225Ac showed… read more here.
Keywords: psma 617; 177lu psma; 225ac psma; tandem therapy ... See more keywords
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-020-05057-6
Abstract: Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide therapy. The PSMA binding affinities, biodistribution, and DNA-damaging capacities of these radiotracers have not yet been compared… read more here.
Keywords: psma 617; 177lu psma; prostate cancer; evaluation ... See more keywords
Costs of radium-223 and the pharmacy preparation 177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitals.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2183618
Abstract: OBJECTIVE The radiopharmaceuticals radium-223 and the pharmacy preparation 177Lu-PSMA-I&T are reimbursed in the Netherlands for metastatic castration-resistant prostate cancer (mCRPC) treatment. Although shown to be life-prolonging in patients with mCRPC, the treatment procedures associated with… read more here.
Keywords: per patient; patient costs; 177lu psma; radium 223 ... See more keywords
Effective half-life, excretion and radiation exposure of 177Lu-PSMA.
Sign Up to like & getrecommendations! Published in 2023 at "Radiation protection dosimetry"
DOI: 10.1093/rpd/ncad141
Abstract: The study aims to evaluate the radiation safety conditions by detecting the patient's urine excretion rate, calculating the effective half-life, and determining the retention of 177Lu-PSMA in the body. Urine samples of patients were collected… read more here.
Keywords: effective half; 177lu psma; half life; radiation ... See more keywords
Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C.
Sign Up to like & getrecommendations! Published in 2020 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001327
Abstract: BACKGROUND We aimed first to evaluate the early oxidative stress following radionuclide therapy (RNT) with 177Lu-PSMA and 177Lu-DOTATATE and second to evaluate the protective effect of vitamin C on oxidative stress. MATERIALS AND METHODS Prostate… read more here.
Keywords: group; treatment; 177lu dotatate; stress ... See more keywords
Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters
Sign Up to like & getrecommendations! Published in 2022 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001539
Abstract: Objective In this study, our aim was to evaluate the relationship of the quantitative data obtained from pretreatment 68Ga prostate-specific membrane antigen (PSMA) PET-computerized tomography (PET/CT) with treatment response of the patients with the diagnosis… read more here.
Keywords: 177lu psma; psma; biochemical response; response ... See more keywords
Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
Sign Up to like & getrecommendations! Published in 2023 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001658
Abstract: Purpose For prostate-specific membrane antigen-directed radioligand therapy (PSMA-RLT), [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T are the currently preferred compounds. Recent preclinical studies suggested ~30x higher kidney absorbed dose for [177Lu]Lu-PSMA-I&T compared to [177Lu]Lu-PSMA-617, which may lead to an… read more here.
Keywords: psma 617; 617 177lu; 177lu psma; kidney absorbed ... See more keywords
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000002561
Abstract: Purpose The present study summarizes the first experience with 177Lu-PSMA-617 (177Lu-PSMA) treatment in metastatic castration-resistant prostate cancer (PCa) in our institution. Methods This was an analysis of the first 30 consecutive patients who underwent 177Lu-PSMA… read more here.
Keywords: therapy; first experience; prostate; psma ... See more keywords